{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:54:04Z","timestamp":1783385644794,"version":"3.54.6"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"Supplement_5","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005160","name":"American Society of Transplantation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005160","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with chronic lung disease and lung transplantation have high rates of colonization and infection from multidrug-resistant (MDR) organisms. This article summarizes the current state of knowledge regarding phage therapy in the setting of lung transplantation. Phage therapy has been used in several lung transplant candidates and recipients on a compassionate use basis targeting mostly MDR gram-negative infections and atypical mycobacterial infections with demonstrated clinical safety. Phage biodistribution given intravenously or via nebulization has not been extensively studied, though preliminary data are presented. Phage interacts with both the innate and adaptive immune system; current literature demonstrates the development of serum neutralization in some cases of phage therapy, although the clinical impact seems variable. A summary of current clinical trials involving patients with chronic lung disease is presented, though none are specifically targeting lung transplant candidates or recipients. In addition to treatment of active infections, a variety of clinical scenarios may benefit from phage therapy, and well-designed clinical trials involving this vulnerable patient population are needed: pre- or peritransplantation use of phage in the setting of MDR organism colonization may lead to waitlisting of candidates currently declined by many centers, along with potential reduction of waitlist mortality rates and posttransplant infections; phage may be used for biofilm-related bronchial stent infections; and, finally, there is a possibility that phage use can affect allograft function and chronic rejection.<\/jats:p>","DOI":"10.1093\/cid\/ciad528","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T02:27:43Z","timestamp":1699324063000},"page":"S416-S422","source":"Crossref","is-referenced-by-count":10,"title":["Phage Therapy in Lung Transplantation: Current Status and Future Possibilities"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4051-5629","authenticated-orcid":false,"given":"Saima","family":"Aslam","sequence":"first","affiliation":[{"name":"Center for Innovative Phage Applications and Therapeutics, Division of Infectious Diseases and Global Public Health, University of California San Diego , La Jolla, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"2023110702272300100_ciad528-B1","doi-asserted-by":"crossref","first-page":"e00954-17","DOI":"10.1128\/AAC.00954-17","article-title":"Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection","volume":"61","author":"Schooley","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023110702272300100_ciad528-B2","doi-asserted-by":"crossref","first-page":"ofaa389","DOI":"10.1093\/ofid\/ofaa389","article-title":"Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States","volume":"7","author":"Aslam","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023110702272300100_ciad528-B3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/cid\/ciac453","article-title":"Phage therapy of Mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial disease","volume":"76","author":"Dedrick","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023110702272300100_ciad528-B4","doi-asserted-by":"crossref","first-page":"e0207121","DOI":"10.1128\/aac.02071-21","article-title":"Considerations for the use of phage therapy in clinical practice","volume":"66","author":"Suh","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023110702272300100_ciad528-B5","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.healun.2021.07.021","article-title":"The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-eighth adult lung transplantation report\u20142021; focus on recipient characteristics","volume":"40","author":"Chambers","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"2023110702272300100_ciad528-B6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.healun.2019.01.1306","article-title":"Outcomes in cystic fibrosis lung transplant recipients infected with organisms labeled as pan-resistant: an ISHLT registry\u2012based analysis","volume":"38","author":"Lay","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"2023110702272300100_ciad528-B7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ccm.2022.10.009","article-title":"Conventional and novel approaches to immunosuppression in lung transplantation","volume":"44","author":"Patterson","year":"2023","journal-title":"Clin Chest Med"},{"key":"2023110702272300100_ciad528-B8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.healun.2021.04.011","article-title":"Cystic Fibrosis Foundation consensus statements for the care of cystic fibrosis lung transplant recipients","volume":"40","author":"Shah","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"2023110702272300100_ciad528-B9","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1093\/cid\/ciad072","article-title":"1-year outcomes of lung transplantation for coronavirus disease 2019\u2013associated end-stage lung disease in the United States","volume":"76","author":"Okumura","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023110702272300100_ciad528-B10","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.3390\/microorganisms9081773","article-title":"Multi-drug resistance bacterial infections in critically ill patients admitted with COVID-19","volume":"9","author":"Pasero","year":"2021","journal-title":"Microorganisms"},{"key":"2023110702272300100_ciad528-B11","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1111\/ajt.15503","article-title":"Early clinical experience of bacteriophage therapy in 3 lung transplant recipients","volume":"19","author":"Aslam","year":"2019","journal-title":"Am J Transplant"},{"key":"2023110702272300100_ciad528-B12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/v13010060","article-title":"A case of phage therapy against pandrug-resistant Achromobacter xylosoxidans in a 12-year-old lung-transplanted cystic fibrosis patient","volume":"13","author":"Lebeaux","year":"2021","journal-title":"Viruses"},{"key":"2023110702272300100_ciad528-B13","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus","volume":"25","author":"Dedrick","year":"2019","journal-title":"Nat Med"},{"key":"2023110702272300100_ciad528-B14","doi-asserted-by":"crossref","first-page":"e14041","DOI":"10.1111\/tid.14041","article-title":"Phage therapy in a lung transplant recipient with cystic fibrosis infected with multidrug-resistant Burkholderia multivorans","volume":"25","author":"Haidar","year":"2023","journal-title":"Transplant Infect Dis"},{"key":"2023110702272300100_ciad528-B15","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s15010-019-01319-0","article-title":"Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient","volume":"47","author":"Law","year":"2019","journal-title":"Infection"},{"key":"2023110702272300100_ciad528-B16","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1007\/s11095-017-2213-4","article-title":"Anti-tuberculosis bacteriophage D29 delivery with a vibrating mesh nebulizer, jet nebulizer, and soft mist inhaler","volume":"34","author":"Carrigy","year":"2017","journal-title":"Pharm Res"},{"key":"2023110702272300100_ciad528-B17","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ijpharm.2018.11.026","article-title":"Jet nebulization of bacteriophages with different tail morphologies\u2014structural effects","volume":"554","author":"Leung","year":"2019","journal-title":"Int J Pharm"},{"key":"2023110702272300100_ciad528-B18","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3390\/v15030602","article-title":"Administration of bacteriophages via nebulization during mechanical ventilation: in vitro study and lung deposition in macaques","volume":"15","author":"Le Guellec","year":"2023","journal-title":"Viruses"},{"key":"2023110702272300100_ciad528-B19","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1111\/bph.15526","article-title":"Inhaled bacteriophage therapy in a porcine model of pneumonia caused by Pseudomonas aeruginosa during mechanical ventilation","volume":"178","author":"Guillon","year":"2021","journal-title":"Br J Pharmacol"},{"key":"2023110702272300100_ciad528-B20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.addr.2021.02.017","article-title":"Dry powder pharmaceutical biologics for inhalation therapy","volume":"172","author":"Chang","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"2023110702272300100_ciad528-B21","doi-asserted-by":"crossref","first-page":"15242","DOI":"10.1038\/s41598-019-51742-4","article-title":"Improved lyophilization conditions for long-term storage of bacteriophages","volume":"9","author":"Manohar","year":"2019","journal-title":"Sci Rep"},{"key":"2023110702272300100_ciad528-B22","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/microorganisms8020282","article-title":"Development of a lyophilization process for Campylobacter bacteriophage storage and transport","volume":"8","author":"Liang","year":"2020","journal-title":"Microorganisms"},{"key":"2023110702272300100_ciad528-B23","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1007\/s11095-016-1892-6","article-title":"Production of inhalation phage powders using spray freeze drying and spray drying techniques for treatment of respiratory infections","volume":"33","author":"Leung","year":"2016","journal-title":"Pharm Res"},{"key":"2023110702272300100_ciad528-B24","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/med.21572","article-title":"Phage therapy: what factors shape phage pharmacokinetics and bioavailability? Systematic and critical review","volume":"39","author":"D\u0105browska","year":"2019","journal-title":"Med Res Rev"},{"key":"2023110702272300100_ciad528-B25","doi-asserted-by":"crossref","first-page":"e01470-20","DOI":"10.1128\/AAC.01470-20","article-title":"Pharmacokinetics and time-kill study of inhaled antipseudomonal bacteriophage therapy in mice","volume":"65","author":"Chow","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023110702272300100_ciad528-B26","doi-asserted-by":"crossref","first-page":"684704","DOI":"10.3389\/fcimb.2021.684704","article-title":"Pharmacokinetics and pharmacodynamics of a novel virulent Klebsiella phage kp_pokalde_002 in a mouse model","volume":"11","author":"Dhungana","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"2023110702272300100_ciad528-B27","doi-asserted-by":"crossref","first-page":"e0003723","DOI":"10.1128\/aac.00037-23","article-title":"Therapeutic potential of intravenous phage as standalone therapy for recurrent drug-resistant urinary tract infections","volume":"67","author":"Le","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2023110702272300100_ciad528-B28","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s41591-021-01403-9","article-title":"Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection","volume":"27","author":"Dedrick","year":"2021","journal-title":"Nat Med"},{"key":"2023110702272300100_ciad528-B29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev-med-080219-122208","article-title":"Phage therapy for antibiotic-resistant bacterial infections","volume":"73","author":"Hatfull","year":"2022","journal-title":"Annu Rev Med"},{"key":"2023110702272300100_ciad528-B30","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/TP.0000000000003565","article-title":"Therapeutic perspectives and mechanistic insights of phage therapy in allotransplantation","volume":"105","author":"Dery","year":"2021","journal-title":"Transplantation"},{"key":"2023110702272300100_ciad528-B31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/v11010010","article-title":"Interactions between bacteriophage, Bacteria, and the mammalian immune system","volume":"11","author":"Van Belleghem","year":"2018","journal-title":"Viruses"},{"key":"2023110702272300100_ciad528-B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2023.04.008","article-title":"Immunogenicity of bacteriophages","author":"Champagne-Jorgensen","journal-title":"Trends Microbiol"},{"key":"2023110702272300100_ciad528-B33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.chom.2017.06.018","article-title":"Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen","volume":"22","author":"Roach","year":"2017","journal-title":"Cell Host Microbe"},{"key":"2023110702272300100_ciad528-B34","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.dld.2015.07.008","article-title":"The human gut microbiota and virome: potential therapeutic implications","volume":"47","author":"Scarpellini","year":"2015","journal-title":"Dig Liver Dis"},{"key":"2023110702272300100_ciad528-B35","doi-asserted-by":"crossref","first-page":"e01874-17","DOI":"10.1128\/mBio.01874-17","article-title":"Bacteriophage transcytosis provides a mechanism to cross epithelial cell layers","volume":"8","author":"Nguyen","year":"2017","journal-title":"mBio"},{"key":"2023110702272300100_ciad528-B36","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.3390\/v7082845","article-title":"Oral application of T4 phage induces weak antibody production in the gut and in the blood","volume":"7","author":"Majewska","year":"2015","journal-title":"Viruses"},{"key":"2023110702272300100_ciad528-B37","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.3390\/v13102049","article-title":"Phage therapy related microbial succession associated with successful clinical outcome for a recurrent urinary tract infection","volume":"13","author":"Terwilliger","year":"2021","journal-title":"Viruses"},{"key":"2023110702272300100_ciad528-B38","doi-asserted-by":"crossref","first-page":"ofac194","DOI":"10.1093\/ofid\/ofac194","article-title":"Nebulized bacteriophage in a patient with refractory Mycobacterium abscessus lung disease","volume":"9","author":"Dedrick","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023110702272300100_ciad528-B39","doi-asserted-by":"crossref","first-page":"e208-20","DOI":"10.1016\/S1473-3099(21)00612-5","article-title":"Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review","volume":"22","author":"Uyttebroek","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2023110702272300100_ciad528-B40","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/MOT.0000000000001029","article-title":"Role of bacteriophage therapy for resistant infections in transplant recipients","volume":"27","author":"Nicholls","year":"2022","journal-title":"Curr Opin Organ Transplant"},{"key":"2023110702272300100_ciad528-B41","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/QCO.0000000000000658","article-title":"Bacteriophage therapy as a treatment option for transplant infections","volume":"33","author":"Aslam","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"2023110702272300100_ciad528-B42","author":"UC San Diego School of Medicine."},{"key":"2023110702272300100_ciad528-B43","doi-asserted-by":"crossref","first-page":"220121","DOI":"10.1183\/16000617.0121-2022","article-title":"Phage therapy for pulmonary infections: lessons from clinical experiences and key considerations","volume":"31","author":"Mitropoulou","year":"2022","journal-title":"Eur Respir Rev"},{"key":"2023110702272300100_ciad528-B44","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/j.1600-6143.2008.02186.x","article-title":"Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex","volume":"8","author":"Alexander","year":"2008","journal-title":"Am J Transplant"},{"key":"2023110702272300100_ciad528-B45","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1513\/AnnalsATS.201606-431OC","article-title":"Reemergence of lower-airway microbiota in lung transplant patients with cystic fibrosis","volume":"13","author":"Syed","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2023110702272300100_ciad528-B46","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.healun.2021.04.014","article-title":"The lung microbiome in lung transplantation","volume":"40","author":"McGinniss","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"2023110702272300100_ciad528-B47","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S2213-2600(20)30405-7","article-title":"Lung microbiota predict chronic rejection in healthy lung transplant recipients: a prospective cohort study","volume":"9","author":"Combs","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2023110702272300100_ciad528-B48","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1183\/09031936.00068310","article-title":"A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation","volume":"37","author":"Vos","year":"2011","journal-title":"Eur Respir J"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/Supplement_5\/S416\/52724824\/ciad528.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/Supplement_5\/S416\/52724824\/ciad528.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T02:28:02Z","timestamp":1699324082000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/77\/Supplement_5\/S416\/7334981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":48,"journal-issue":{"issue":"Supplement_5","published-online":{"date-parts":[[2023,11,2]]},"published-print":{"date-parts":[[2023,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad528","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,1]]},"published":{"date-parts":[[2023,11,1]]}}}